Review: Pharmacological approaches to reduce adiposity

Abstract

A catalogue of antiobesity agents came and went during the last century. The current weight loss agents orlistat and sibutramine are now to be joined by rimonabant, a cannabinoid-1 (CB1) receptor antagonist that acts centrally to decrease appetite and peripherally to reduce lipogenesis in adipose tissue. Use of rimonabant is based on evidence that the endogenous cannabinoid system is overactive in obesity, mainly due to increased expression of CB1 receptors. Weight loss attributed to rimonabant (about 5 kg over one year) was associated with improved insulin sensitivity, reduced triglyceride and increased high density lipoprotein cholesterol. Like other antiobesity agents rimonabant should be used as an adjunct to lifestyle advice. Although there are several potential antiobesity agents in development these are mostly at an early stage of clinical evaluation.

Keywords

obesity rimonabant orlistat sibutramine.

Get full access to this article

View all access options for this article.

References

WHO fact sheet: Obesity and overweight 2003. www.who.int/topics/obesity/en/ (accessed January 2005).

UK national audit office. Tackling obesity in England 2003. www.nao.gove.uk/publications/nao_reports/00-01/0001220 (accessed May 2006)

Haslam DW , James WPT. Obesity. Lancet 2005;366:1197-209.

Sjostrom L. , Rissanen A. , Anderson T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.

James WPT , Astrup A. , Finer N. et al. Effect of sibutramine on weight maintenance and weight loss: a randomised trial. Lancet 2000;356: 2119-25.

Li Z. , Maglione M. , Tu W. et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.

Ioannides-Demos LL , Proietto J. , McNeil JJ Pharmacotherapy for obesity. Drugs 2005;65:1391-418.

World Health Organization. Obesity: preventing and managing the global epidemic. Geneva. Switzerland: Report of a WHO consultation, 2000. Technical Report Series 894.

Bray GA Pharmacological treatment of obesity. In Handbook of Obesity , Bray GA , Buchard C , James WPT (eds). New York: Marcel Dekker, 1998, pp 953-75.

10.

Goldstein DJ , Rampey AH , Enas GG et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obesity 1994;18:129-35.

11.

Wilding J. , van Gaal L. , Rissanen A. et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obesity Relat Metab Disord 2004; 28:1399-410.

12.

Gadde KM , Franciscy DM , Wagner HR , Krishman KRR. Zonisamide for weight loss in obese adults. A randomized controlled trial . JAMA 2003; 289:1820-5.

13.

Anderson JW , Greenway FL , Fujioka K. et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity Res 2002;10:633-41.

14.

Heymsfield SB , Greenberg AS , Fujioka K. et al. Recombinant leptin for weight loss in obese and lean adults. A randomized controlled, doseescalation trial. JAMA 1999;282:1568-75.

15.

Ettinger MP , Littlejohn TW , Schwartz SL et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults. A randomized, dose-ranging study. JAMA 2003;289:1826-32.

16.

Cota D. , Marsicano G. , Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.

17.

Di Marzo V. , Bifulco M. , De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.

18.

Pertwee RG Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005;168:1-51.

19.

Van Gaal LF , Rissanen AM , Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389-97.

20.

Despres JP , Golay A. , Sjostrom L. et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 ;353:2121-34.

21.

Pi-Sunyer X. , Aronne LJ , Heshmati HM Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.

22.

Holt R. New drugs for obesity. Diabetes Obesity Metabolism 2004,6:464.

23.

Krentz AJ , Bailey CJ Oral antidiabetic agents. Current role in type 2 diabetes mellitus . Drugs 2005;65:385-411.

24.

Day C. Amylin analogue as an antidiabetic agent. Br J Diabetes Vasc Dis 2005;5:151-4.

25.

Schnabel CA The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes. Br J Diabetes Vasc Dis 2005;5:227-35.

26.

Kendall DM , Riddle MC , Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea . Diabetes Care 2005;28:1083-91.

27.

Batterham RL , Cohen MA , Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY 3-36. New Engl J Med 2003;349:941-8.

28.

Cummings DE , Weigle DS , Frayo RS Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30.

29.

Walker BR 11β-hydroxysteroid dehydrogenase type 1 in obesity. Obesity Res 2004;12:1-3.

30.

Evans RM , Barish GD , Wang YX PPARs and the complex journey to obesity. Nature Med 2004;10:1-7.

31.

Hoodia gordonii o http://www.phytopharm.co.uk/hoodia_faq.html (accessed May 2006).

32.

MacLean DB , Luo LG Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside . Brain Res 2004;1020:1-11.